Anatol Kreitzer, the Chief Discovery Officer at MapLight Therapeutics, reported a sale of 3,316 shares of the companys Voting Common Stock on April 15, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at a weighted average price of $26.61, yielding roughly $88,238 in proceeds.
The disposals were executed across multiple trades, with individual transaction prices ranging narrowly from $26.6045 to $26.6093. Following these transactions, Kreitzer retains direct ownership of 256,612 shares of MapLight Therapeutics.
Company stock subsequently strengthened in the market, moving to $30.05 and marking a 12% increase over the prior week. The shares are trading near their 52-week high of $31.13.
The filing specifies that the sale was intended to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units. Data from InvestingPro, cited in conjunction with the filing, indicates the stock is currently overvalued relative to its Fair Value and notes the availability of 12 additional ProTips for subscribers who are analyzing the companys momentum and financial health.
Analyst attention has been notable in recent coverage. TD Cowen initiated coverage of MapLight Therapeutics with a buy rating, pointing to the companys pipeline in central nervous system and neuropsychiatric conditions and highlighting the lead asset, ML-007C-MA. TD Cowen expects Phase II data in the third quarter of this year.
Stifel also reaffirmed a buy rating and set a $28.00 price target after MapLights fourth-quarter update. Stifel noted that the Phase 2 data for ML-007C-MA remains on track for a topline readout in the third quarter of 2026. The firm described the M1/M4 mechanism as de-risked by the drug Cobenfy and said it is looking to confirm efficacy with potential differentiation in tolerability, safety, or once-daily dosing.
Taken together, the insider sale to cover tax obligations, short-term share appreciation, valuation signals from InvestingPro, and recent analyst coverage underscore the mix of near-term market activity and forward-looking clinical milestones that are shaping investor attention toward MapLight Therapeutics.
Key points
- Anatol Kreitzer sold 3,316 shares on April 15, 2026 at a weighted average of $26.61, generating about $88,238.
- MapLight stock has risen to $30.05, up 12% in the last week and trading close to a 52-week high of $31.13.
- Analysts from TD Cowen and Stifel maintain positive views, focusing on lead asset ML-007C-MA and an anticipated Phase II readout in the third quarter of 2026.
Risks and uncertainties
- Valuation risk - InvestingPro data flags the stock as overvalued relative to its Fair Value, which may affect investor expectations.
- Clinical timeline uncertainty - The market is focused on a Phase II readout expected in the third quarter of 2026; timing and results are material to the companys outlook.
- Perception risk from insider transactions - Although the sale was disclosed as covering tax withholding tied to RSU vesting, insider sales can influence market sentiment for biotech and healthcare stocks.